Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

NCT ID: NCT00296010

Last Updated: 2021-02-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 77 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-08-31
• Study Completion Date: 2011-12-31

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, and liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving liposomal doxorubicin after surgery is more effective than observation or cyclophosphamide and methotrexate in treating breast cancer.

PURPOSE: This randomized phase III trial is studying liposomal doxorubicin to see how well it works compared with observation or cyclophosphamide and methotrexate in treating older women who have undergone surgery for breast cancer.

Detailed Description

OBJECTIVES:

Primary

• Compare the breast cancer-free interval in elderly women with resectable, hormone receptor-negative breast cancer treated with pegylated doxorubicin hydrochloride liposome (PDL) vs observation or PDL vs cyclophosphamide and methotrexate.

Secondary

• Compare the tolerability of these regimens in these patients.
• Compare the safety and toxic effects of these regimens in these patients.
• Compare the overall and progression-free survival of patients treated with these regimens.
• Compare the quality of life of patients treated with these regimens.
• Compare the sites of failure in patients treated with these regimens.
• Compare the competing causes of death in patients treated with these regimens.
• Compare the rate of second non-breast malignancy in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are assigned, based on patient preference, to 1 of 2 treatment groups.

• Group 1: Patients are randomized to 1 of 2 arms (arms I and II).

• Arm I: Patients receive pegylated doxorubicin hydrochloride liposome (PDL) IV over 1 hour on day 1. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
• Arm II: Patients undergo observation only.
• Group 2: Patients are randomized to 1 of 2 treatment arms (arms III and IV).

• Arm III: Patients receive PDL as in arm I.
• Arm IV: Patients receive oral cyclophosphamide once daily on days 1-7 and oral methotrexate twice daily on days 1 and 4. Treatment repeats every week for 16 courses in the absence of disease progression or unacceptable toxicity.

All patients may undergo radiotherapy according to institutional standards either during surgery or after the completion of chemotherapy.

Quality of life is assessed at baseline and at 3, 6, and 12 months.

After completion of study treatment, patients are followed periodically for 1 year.

PROJECTED ACCRUAL: A total of 1,296 patients will be accrued for this study.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CASA-nil PLD

Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks

Group Type: EXPERIMENTAL

pegylated liposomal doxorubicin hydrochloride

Intervention Type: DRUG

Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)

adjuvant therapy

Intervention Type: PROCEDURE

radiation therapy

Intervention Type: RADIATION

Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

CASA-Nil

No adjuvant therapy

Group Type: ACTIVE_COMPARATOR

radiation therapy

Intervention Type: RADIATION

Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

CASA-CM PLD

Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks

Group Type: EXPERIMENTAL

pegylated liposomal doxorubicin hydrochloride

Intervention Type: DRUG

Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)

adjuvant therapy

Intervention Type: PROCEDURE

radiation therapy

Intervention Type: RADIATION

Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

CASA-CM CM

Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks

Group Type: ACTIVE_COMPARATOR

cyclophosphamide

Intervention Type: DRUG

cyclophosphamide 50 mg/day orally continuously for 16 weeks

methotrexate

Intervention Type: DRUG

methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks

adjuvant therapy

Intervention Type: PROCEDURE

radiation therapy

Intervention Type: RADIATION

Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

Interventions

cyclophosphamide

cyclophosphamide 50 mg/day orally continuously for 16 weeks

Intervention Type: DRUG

methotrexate

methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks

Intervention Type: DRUG

pegylated liposomal doxorubicin hydrochloride

Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)

Intervention Type: DRUG

adjuvant therapy

Intervention Type: PROCEDURE

radiation therapy

Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed breast cancer

• Disease must be confined to the breast and axillary nodes without detected masses elsewhere
• No history of prior ipsilateral or contralateral invasive breast cancer
• Resected disease

• No more than 16 weeks since last surgery to remove the tumor
• No known clinical residual locoregional disease
• Margins must be negative for invasive breast cancer and ductal carcinoma in situ
• No locally advanced, inoperable breast cancer including any of the following:

• Inflammatory breast cancer
• Supraclavicular node involvement
• Enlarged internal mammary nodes unless pathologically negative
• Synchronous bilateral invasive breast cancer (diagnosed in the past 2 months) allowed if all tumors are hormone receptor-negative
• Must not be a candidate for endocrine therapy or standard chemotherapy
• Hormone receptor-negative disease

PATIENT CHARACTERISTICS:

• Female
• Menopausal status: postmenopausal
• ECOG performance status 0-2
• Platelet count ≥ 100,000/mm^3
• Granulocyte count ≥ 1,500/mm^3
• WBC ≥ 3,000/mm^3
• AST and ALT ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin normal
• Creatinine clearance ≥ 50 mL/min
• Creatinine < 1.35 mg/dL
• No significant malabsorption syndrome or disease affecting gastrointestinal tract function
• No myocardial infarction within the past 6 months
• No pulmonary embolism within the past 6 months
• No deep vein thrombosis within the past 6 months
• No New York Heart Association class III or IV heart disease
• LVEF ≥ 50% by echocardiography, radionucleotide ventriculography, or MUGA
• No evidence of acute ischemia by ECG
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or bladder, or ipsilateral or contralateral breast carcinoma in situ
• No active, uncontrolled infection
• No active hepatitis B or C virus infection
• No other chronic infection
• Patients must not have any of the following "geriatric syndromes":

• Dementia
• Delirium
• Major depression (as diagnosed by a psychiatrist)
• Recent falls
• Spontaneous bone fractures
• Neglect
• Abuse
• No evidence of medically relevant conduction system abnormalities that would preclude study entry
• No other nonmalignant, uncontrolled systemic diseases, psychiatric illness, or addictive or cognitive disorder that would preclude study participation or compliance

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since prior raloxifene, tamoxifen citrate, or other selective estrogen receptor modulators (SERMs)
• No concurrent recombinant human epoetin alfa or pegfilgrastim
• No prior neoadjuvant or adjuvant therapy for breast cancer except radiotherapy
• Concurrent trastuzumab (Herceptin®) allowed
• No concurrent hormonal replacement therapy
• No other concurrent hormonal therapy (including estrogen, progesterone, androgens, tamoxifen citrate, SERMs, or aromatase inhibitors) except for the following:

• Steroids for adrenal failure
• Hormones for non-disease-related conditions (e.g., insulin for diabetes)
• Intermittent dexamethasone as an antiemetic
• No other concurrent investigational agents
• No concurrent bisphosphonates, except for the treatment of osteoporosis
• For patients who received prior anthracyclines, the following criteria must be met:

• Cumulative dose ≤ 240 mg/m² for conventional doxorubicin

• ≤ 140 mg/m² in case of prior doxorubicin and left chest radiotherapy (LCRT)
• Cumulative dose ≤ 400 mg/m² for epirubicin

• ≤ 230 mg/m² in case of prior epirubicin and LCRT

• Minimum Eligible Age: 66 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

ETOP IBCSG Partners Foundation

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Diana Crivellari, MD

Role: STUDY_CHAIR

Centro di Riferimento Oncologico, Aviano (Italy)

Silvia Dellapasqua, MD

Role: STUDY_CHAIR

European Institute of Oncology, Milano (Italy)

Anne Hamilton, MD

Role: STUDY_CHAIR

Royal Prince Alfred Hospital, Camperdown (Australia)

Locations

Gosford Hospital

Gosford, New South Wales, Australia

Nepean Cancer Care Centre at Nepean Hospital

Kingswood, New South Wales, Australia

Royal Hobart Hospital

Hobart, Tasmania, Australia

Frankston Hospital

Frankston, Victoria, Australia

Institut Jules Bordet

Brussels, , Belgium

Centre Hospitalier Etterbeek Ixelles

Brussels, , Belgium

AZ Groeninge - Oncologisch Centrum

Kortrijk, , Belgium

U.Z. Gasthuisberg

Leuven, , Belgium

CHU Liege - Domaine Universitaire du Sart Tilman

Liège, , Belgium

National Institute of Oncology

Budapest, , Hungary

Centro di Riferimento Oncologico - Aviano

Aviano, , Italy

Ospedali Riuniti di Bergamo

Bergamo, , Italy

Ospedale degli Infermi - ASL 12

Biella, , Italy

Ospedale Civile Ramazzini

Carpi, , Italy

Ospedale Civile S. Croce

Fano, , Italy

European Institute of Oncology

Milan, , Italy

Ospedale Civile Rimini

Rimini, , Italy

Ospedale Sant' Eugenio

Rome, , Italy

Centro Sociale Oncologico

Treste, , Italy

Policlinico Universitario Udine

Udine, , Italy

Ospedale di Circolo e Fondazione Macchi

Varese, , Italy

Auckland City Hospital

Auckland, , New Zealand

Institutul Oncologic - Universitatea de Medicina

Cluj-Napoca, , Romania

Institute of Oncology - Ljubljana

Ljubljana, , Slovenia

Sahlgrenska University Hospital

Gothenburg, , Sweden

Skaraborgs Hospital

Skövde, , Sweden

Kantonspital Aarau

Aarau, , Switzerland

Inselspital Bern

Bern, , Switzerland

Oncocare Sonnenhof-Klinik Engeriedspital

Bern, , Switzerland

Kantonsspital Graubuenden

Chur, , Switzerland

Ospedale Beata Vergine

Mendrisio, , Switzerland

Kantonsspital - St. Gallen

Sankt Gallen, , Switzerland

Regionalspital

Thun, , Switzerland

Countries

Australia; Belgium; Hungary; Italy; New Zealand; Romania; Slovenia; Sweden; Switzerland

Other Identifiers

IBCSG-32-05

Identifier Type: OTHER

Identifier Source: secondary_id

BIG-CASA

Identifier Type: OTHER

Identifier Source: secondary_id

2005-003434-18

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BIG-1-05

Identifier Type: OTHER

Identifier Source: secondary_id

EU-205112

Identifier Type: -

Identifier Source: secondary_id

CDR0000463710

Identifier Type: -

Identifier Source: org_study_id